Ventyx Biosciences, Inc. (VTYX)
Mar 4, 2026 - VTYX was delisted (reason: acquired by LLY)
14.00
+0.02 (0.14%)
Inactive · Last trade price on Mar 3, 2026

Ventyx Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Income
-116.72-148.45-207.99-113.14-67.15-7.05
Net Income
-106.61-135.12-192.96-108.43-82.19-28.17
Earnings Per Share
-1.50-1.97-3.30-2.07-6.65-14.17
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
192.64217.32252.22317.94258.580.24
Total Debt
10.0210.7912.511.5600
Net Cash (Debt)
182.61206.53239.71316.38258.580.24
Net Cash Growth
-30.77%-13.84%-24.23%22.36%105873.77%0%
Net Cash Per Share
2.573.024.096.0320.160.12

Cash Flow & CapEx

Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-87.75-130.87-166.52-98.77-38.65-6.2
Capital Expenditures
-0.11-0.24-0.51-0.28-0.26-
Free Cash Flow
-87.87-131.11-167.04-99.05-38.91-6.2
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.